|
|
Article: US FDA Grants IND to Bavarian Nordic, Trial with IMVAMUNE Smallpox Vaccine in Atopic Dermatitis to Start.
- Article from:
- PR Newswire
- Article date:
- May 5, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
COPENHAGEN, Denmark, May 5 /PRNewswire/ --
Bavarian Nordic A/S announced today that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug Application (IND) for its third-generation smallpox vaccine candidate to enter further clinical trials. Bavarian Nordic will immediately start a Phase l study with IMVAMUNE(TM), its safe third-generation smallpox vaccine, in 60 subjects including persons suffering from atopic dermatitis. This study will be conducted in Europe with the final report expected in 2005.
Persons with atopic dermatitis, more commonly known as eczema, are at risk in suffering potentially severe side ...